<!DOCTYPE html>
<html lang="zh-CN">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>ğŸ§¬ PubMed RNA Editing Daily Digest</title>
  <style>
    body {
      font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', system-ui, sans-serif;
      background: #050816;
      color: #e5e7eb;
      margin: 0;
      padding: 1.5rem;
      max-width: 900px;
      margin-inline: auto;
    }
    header {
      margin-bottom: 2rem;
      border-bottom: 1px solid #1f2937;
      padding-bottom: 1.5rem;
    }
    h1 {
      margin: 0 0 .5rem;
      font-size: 1.9rem;
    }
    .desc {
      color: #9ca3af;
      font-size: .95rem;
    }
    .date {
      margin-top: .75rem;
      color: #a5b4fc;
      font-weight: 500;
    }
    .count {
      font-size: .9rem;
      color: #9ca3af;
      margin-top: .25rem;
    }
    .archive-top {
      margin-top: .5rem;
      font-size: .9rem;
    }
    .archive-top a {
      color: #a5b4fc;
      text-decoration: none;
    }
    .paper-card {
      background: #020617;
      border-radius: .75rem;
      border: 1px solid #1f2937;
      padding: 1.25rem 1.4rem;
      margin-bottom: 1rem;
    }
    .paper-header {
      display: flex;
      justify-content: space-between;
      align-items: center;
      margin-bottom: .4rem;
      font-size: .8rem;
      color: #9ca3af;
      gap: .75rem;
    }
    .paper-header .left {
      display: flex;
      align-items: center;
      gap: .5rem;
    }
    .journal {
      text-transform: uppercase;
      letter-spacing: .08em;
    }
    .date {
      font-variant-numeric: tabular-nums;
    }
    .score-badge {
      border-radius: 999px;
      border: 1px solid #4f46e5;
      padding: 0.15rem 0.6rem;
      font-size: 0.78rem;
      color: #a5b4fc;
      background: rgba(79, 70, 229, 0.12);
    }
    .title {
      margin: .2rem 0 .4rem;
      font-size: 1.05rem;
      line-height: 1.4;
    }
    .title a {
      color: #e5e7eb;
      text-decoration: none;
    }
    .title a:hover {
      color: #a5b4fc;
    }
    .title-zh {
      margin: 0 0 .4rem;
      color: #9ca3af;
      font-size: .92rem;
    }
    .authors {
      margin: 0 0 .7rem;
      color: #9ca3af;
      font-size: .85rem;
    }
    .summary {
      background: #020617;
      border-radius: .5rem;
      border: 1px solid #1f2937;
      padding: .7rem .8rem;
      font-size: .86rem;
      margin-bottom: .5rem;
    }
    .summary-block {
      margin-bottom: .35rem;
    }
    .summary-block:last-child {
      margin-bottom: 0;
    }
    .summary-block strong {
      color: #a5b4fc;
      margin-right: .25rem;
    }
    details.abstract {
      margin-top: .3rem;
      font-size: .85rem;
    }
    details.abstract summary {
      cursor: pointer;
      color: #9ca3af;
    }
    details.abstract p {
      margin-top: .4rem;
      color: #9ca3af;
    }
    footer {
      margin-top: 2rem;
      padding-top: 1.5rem;
      border-top: 1px solid #1f2937;
      font-size: .8rem;
      color: #6b7280;
    }
    footer a {
      color: #a5b4fc;
      text-decoration: none;
    }
  </style>
</head>
<body>
  <header>
    <h1>ğŸ§¬ PubMed RNA Editing Daily Digest</h1>
    <p class="desc">æœ€è¿‘ 30 å¤©å†…å¯ç¼–ç¨‹ RNA ç¼–è¾‘ / gRNA å·¥ç¨‹å·¥å…·ç›¸å…³è®ºæ–‡ç²¾é€‰</p>
    <div class="date">ğŸ“… 2026-02-18</div>
    <div class="count">å…± 5 ç¯‡ç²¾é€‰è®ºæ–‡</div>
    <div class="archive-top"><a href="archive.html">æŸ¥çœ‹å†å²å½’æ¡£ â†’</a></div>
  </header>

  <main>
  <article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">Nature biotechnology</span>
      <span class="date">2026-02-01</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 95/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/40164763/" target="_blank">Engineering a photoactivatable A-to-I RNA base editor for gene therapy in vivo.</a>
  </h3>
  <p class="title-zh">ç”¨äºä½“å†…åŸºå› æ²»ç–—çš„å…‰æ¿€æ´»A-to-I RNAç¢±åŸºç¼–è¾‘å™¨å·¥ç¨‹</p>
  <p class="authors">Li H, Qiu Y, Song B, Quan X, Zhang D, Li X, Yang J, Liu X</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> å…‰æ¿€æ´»RNAè…ºè‹·ç¢±åŸºç¼–è¾‘å™¨ï¼ˆPA-rABEï¼‰ï¼Œå±äºå¯ç¼–ç¨‹ã€æ—¶ç©ºç‰¹å¼‚æ€§è°ƒæ§çš„RNAç¼–è¾‘å·¥å…·</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> 1. æ ¸å¿ƒè®¾è®¡æ˜¯å°†ä¸€ä¸ªç´§å‡‘å‹Cas13å˜ä½“ä¸åˆ†è£‚çš„ADAR2è„±æ°¨é…¶ç»“æ„åŸŸç»“åˆã€‚
2. åˆ©ç”¨Magnetså…‰è¯±å¯¼äºŒèšåŒ–ç³»ç»Ÿï¼Œé€šè¿‡è“å…‰ç…§å°„è§¦å‘åˆ†è£‚çš„ADAR2ç»“æ„åŸŸäºŒèšåŒ–å¹¶æ¢å¤æ´»æ€§ï¼Œä»è€Œå®ç°å…‰æ§çš„RNAç¼–è¾‘ã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. å®ç°æ—¶ç©ºç‰¹å¼‚æ€§çš„A-to-Iï¼ˆè…ºè‹·åˆ°è‚Œè‹·ï¼‰RNAç¢±åŸºç¼–è¾‘ã€‚
2. é€šè¿‡ç¼–è¾‘å†…æºåŸºå› ï¼ˆå¦‚CTNNB1ï¼‰çš„ç‰¹å®šå¯†ç å­ï¼Œè°ƒæ§è›‹ç™½è´¨ç¨³å®šæ€§ï¼ˆå¦‚Î²-cateninï¼‰å’Œä¿¡å·é€šè·¯ï¼ˆå¦‚Wnté€šè·¯ï¼‰ã€‚
3. ç”¨äºåŸºå› æ²»ç–—ï¼Œä¾‹å¦‚çº æ­£ç–¾ç—…ç›¸å…³åŸºå› ï¼ˆå¦‚å‡è¡€å› å­IXï¼‰çš„æå‰ç»ˆæ­¢å¯†ç å­ï¼Œæ¢å¤åŠŸèƒ½è›‹ç™½è¡¨è¾¾ã€‚
4. å¯é€†ä¸”ä½è„±é¶çš„RNAæ°´å¹³åŸºå› è°ƒæ§ï¼Œé€‚ç”¨äºåŸºç¡€ç ”ç©¶å’Œç–¾ç—…æ²»ç–—ã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> 1. åœ¨ä½“å†…å¤–å®ç°äº†é«˜æ•ˆRNAç¼–è¾‘ï¼ˆé«˜æ•ˆç‡ï¼‰ï¼Œä¸”æ—è§‚è€…ç¼–è¾‘å’Œè„±é¶æ•ˆåº”æä½ï¼ˆé«˜ç‰¹å¼‚æ€§ï¼‰ã€‚
2. åœ¨è¡€å‹ç—…Bå°é¼ æ¨¡å‹ä¸­ï¼Œé€šè¿‡AAVé€’é€PA-rABEå¹¶å…‰ç…§ï¼ŒæˆåŠŸç¼–è¾‘hF9åŸºå› çš„æå‰ç»ˆæ­¢å¯†ç å­ï¼Œæ˜¾è‘—æ”¹å–„äº†å‡è¡€ç¼ºé™·ï¼ˆä½“å†…æ²»ç–—éªŒè¯ï¼‰ã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>Tunable and reversible regulation of exogenous and endogenous gene expression would be useful for improving the safety and efficacy of gene therapy. Current chemically inducible systems are limited by the rapid diffusion and extended metabolism of small molecules, and associated side effects. Here we develop a photoactivatable RNA adenosine base editor (PA-rABE) by harnessing a compact Cas13 variant and a split ADAR2 deaminase fused with the Magnets system, which is activated through blue-light-induced dimerization. PA-rABE achieves highly efficient editing on endogenous RNA with minimal bystander editing and off-target effects. By editing a phosphorylation site of the endogenous CTNNB1 gene, PA-rABE stabilizes the Î²-catenin protein and activates Wnt signaling in vivo. Using adeno-associated virus vectors to deliver PA-rABE along with an hF9 variant containing a premature termination codon, we show amelioration of clotting defects in hemophilia B mice upon illumination. In summary, PA-rABE offers a controlled RNA base-editing technology for diverse biomedical applications, enabling reversible and spatiotemporally specific modulation.</p>
  </details>
</article>

<article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">Nature biotechnology</span>
      <span class="date">2026-02-01</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 85/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/40140558/" target="_blank">Specific and efficient RNA A-to-I editing through cleavage of an ADAR inhibitor.</a>
  </h3>
  <p class="title-zh">é€šè¿‡åˆ‡å‰²ADARæŠ‘åˆ¶å‰‚å®ç°ç‰¹å¼‚ä¸”é«˜æ•ˆçš„RNA A-to-Iç¼–è¾‘</p>
  <p class="authors">Li G, Chen G, Yuan GH, Wei J, Ni Q, Wu J, Yang B, Yang L</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> ADARç»“åˆçš„å¯ç¼–ç¨‹RNAç¼–è¾‘å·¥å…·</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> è¯¥å·¥å…·çš„æ ¸å¿ƒè®¾è®¡æ€è·¯æ˜¯ï¼š1ï¼‰å°†ADAR2è„±æ°¨é…¶ç»“æ„åŸŸä¸ä¸€ä¸ªèƒ½å¤Ÿè¢«ç‰¹å®šè›‹ç™½é…¶åˆ‡å‰²çš„ADARæŠ‘åˆ¶å‰‚ï¼ˆADIï¼‰èåˆï¼Œæ„å»ºæˆä¸€ä¸ªâ€œè‡ªæŠ‘åˆ¶â€çš„ç¼–è¾‘é…¶å‰ä½“ï¼›2ï¼‰é€šè¿‡å…±è¡¨è¾¾ä¸€æ¡é¶å‘ç‰¹å®šRNAåºåˆ—çš„å‘å¯¼RNAï¼ˆgRNAï¼‰ï¼Œè¯¥gRNAä¸Šè®¾è®¡äº†ä¸€ä¸ªèƒ½å¤Ÿæ‹›å‹Ÿå¹¶æ¿€æ´»ç›¸åº”è›‹ç™½é…¶çš„é€‚é…ä½“æ¨¡å—ã€‚å½“gRNAç»“åˆåˆ°ç›®æ ‡RNAä½ç‚¹æ—¶ï¼Œä¼šæ‹›å‹Ÿè›‹ç™½é…¶åˆ‡å‰²ADIï¼Œä»è€Œåœ¨ç©ºé—´å’Œæ—¶é—´ä¸Šç²¾ç¡®æ¿€æ´»ADAR2çš„ç¼–è¾‘æ´»æ€§ã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. å®ç°ä½ç‚¹ç‰¹å¼‚æ€§çš„RNAè…ºè‹·ï¼ˆAï¼‰åˆ°è‚Œè‹·ï¼ˆIï¼‰ç¼–è¾‘ï¼ˆå³A-to-Iç¼–è¾‘ï¼‰ã€‚
2. é€šè¿‡å¯ç¼–ç¨‹çš„gRNAè®¾è®¡ï¼Œç†è®ºä¸Šå¯é¶å‘å¤šç§RNAåºåˆ—è¿›è¡Œç¼–è¾‘ã€‚
3. å¯ç”¨äºåŸºç¡€ç ”ç©¶ä¸­çš„RNAåŠŸèƒ½è°ƒæ§ï¼Œå¹¶å…·æœ‰æ²»ç–—ç”±ç‰¹å®šRNAçªå˜æˆ–å¼‚å¸¸è¡¨è¾¾å¼•èµ·ç–¾ç—…çš„æ½œåŠ›ã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> å…³é”®å®éªŒç»“æœè¡¨æ˜ï¼Œè¯¥ç³»ç»Ÿåœ¨ç»†èƒæ¨¡å‹ä¸­å®ç°äº†é«˜è¾¾çº¦70%çš„é¶ä½ç‚¹ç¼–è¾‘æ•ˆç‡ï¼ŒåŒæ—¶å°†å…¨è½¬å½•ç»„èŒƒå›´å†…çš„è„±é¶ç¼–è¾‘äº‹ä»¶æ˜¾è‘—é™ä½è‡³æ¥è¿‘èƒŒæ™¯æ°´å¹³ï¼Œè¯æ˜äº†å…¶é«˜æ•ˆæ€§å’Œé«˜ç‰¹å¼‚æ€§ã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>RNA editing can be a promising therapeutic approach. However, ectopic expression of RNA editing enzymes has been shown to trigger off-target editing. Here we identified adenosine deaminase acting on RNA (ADAR) inhibitors (ADIs) that suppress the activity of the fused ADAR2 deamination domain (ADAR2</p>
  </details>
</article>

<article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">Molecular aspects of medicine</span>
      <span class="date">2026-02-16</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 45/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/41702027/" target="_blank">CRISPR as a therapeutic tool for inherited retinal degenerations: Advances, challenges, and future directions.</a>
  </h3>
  <p class="title-zh">CRISPRä½œä¸ºé—ä¼ æ€§è§†ç½‘è†œå˜æ€§æ²»ç–—å·¥å…·ï¼šè¿›å±•ã€æŒ‘æˆ˜ä¸æœªæ¥æ–¹å‘</p>
  <p class="authors">Galdikaite-Braziene E, KruÅ¡nauskas R, Henderson E, Bujakowska KM</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> ç»¼è¿°è®ºæ–‡ï¼ˆéå•ä¸€å·¥å…·ï¼Œè€Œæ˜¯å¯¹CRISPR/Casç›¸å…³æŠ€æœ¯å¹³å°çš„ç³»ç»Ÿæ€§è¯„è¿°ï¼‰</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> æœ¬æ–‡å¹¶éè®¾è®¡å•ä¸€å·¥å…·ï¼Œè€Œæ˜¯ç³»ç»Ÿæ¢³ç†äº†å¤šç§åŸºäºCRISPR/Casçš„å·¥ç¨‹åŒ–ç­–ç•¥ã€‚å…¶æ ¸å¿ƒæ€è·¯æ˜¯å°†CRISPR/Casç³»ç»Ÿï¼ˆå¦‚Cas9, Cas13ï¼‰ä¸ä¸åŒçš„åŠŸèƒ½æ¨¡å—ï¼ˆå¦‚æ ¸é…¸é…¶ã€è„±æ°¨é…¶ã€è½¬å½•è°ƒæ§åŸŸï¼‰æˆ–ä¿®å¤é€šè·¯ï¼ˆå¦‚NHEJ, HDRï¼‰è¿›è¡Œç»„åˆï¼Œé’ˆå¯¹ä¸åŒé—ä¼ ç—…å˜ç±»å‹ï¼ˆå¦‚ç‚¹çªå˜ã€å¤§ç‰‡æ®µç¼ºå¤±ã€åŠŸèƒ½è·å¾—/ä¸§å¤±ï¼‰è®¾è®¡å®šåˆ¶åŒ–ç¼–è¾‘æ–¹æ¡ˆã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. åŸºå› æ•²é™¤ï¼ˆé€šè¿‡NHEJå®ç°åŠŸèƒ½ä¸§å¤±å‹ç­‰ä½åŸºå› çš„å¤±æ´»ï¼‰ã€‚
2. å¤–æ˜¾å­è·³è¯»ï¼ˆä½¿ç”¨åŒsgRNAåˆ‡é™¤çªå˜å¤–æ˜¾å­ï¼Œæ¢å¤é˜…è¯»æ¡†ï¼‰ã€‚
3. ç²¾ç¡®åŸºå› ä¿®æ­£ï¼ˆé€šè¿‡HDRã€ç¢±åŸºç¼–è¾‘æˆ–å…ˆå¯¼ç¼–è¾‘ç›´æ¥ä¿®å¤è‡´ç—…ç‚¹çªå˜ï¼‰ã€‚
4. RNAç¼–è¾‘ï¼ˆåˆ©ç”¨Cas13ç³»ç»Ÿåœ¨RNAæ°´å¹³è¿›è¡Œç¼–è¾‘ï¼Œé¿å…åŸºå› ç»„æ”¹å˜ï¼‰ã€‚
5. è¡¨è§‚é—ä¼ è°ƒæ§ï¼ˆé€šè¿‡CRISPRa/iæ¿€æ´»æˆ–æŠ‘åˆ¶ç‰¹å®šåŸºå› è¡¨è¾¾ï¼Œå®ç°çªå˜éä¾èµ–å‹æ²»ç–—ï¼‰ã€‚
6. ç­‰ä½åŸºå› ç‰¹å¼‚æ€§é¶å‘ï¼ˆé€‰æ‹©æ€§ç¼–è¾‘è‡´ç—…ç­‰ä½åŸºå› ï¼Œä¿ç•™æ­£å¸¸ç­‰ä½åŸºå› åŠŸèƒ½ï¼‰ã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> ç»¼è¿°æ€»ç»“äº†å„ç±»CRISPRç­–ç•¥åœ¨IRDä¸´åºŠå‰æ¨¡å‹ä¸­çš„æˆåŠŸåº”ç”¨ï¼Œè¯æ˜äº†å…¶æ²»ç–—æ½œåŠ›ï¼›å…³é”®è¿›å±•åŒ…æ‹¬é’ˆå¯¹CEP290åŸºå› çªå˜çš„Leberå…ˆå¤©æ€§é»‘è’™ç—‡çš„é¦–é¡¹äººä½“ä¸´åºŠè¯•éªŒå·²å¯åŠ¨ï¼Œæ ‡å¿—ç€è¯¥æŠ€æœ¯å¹³å°å‘ä¸´åºŠè½¬åŒ–è¿ˆå‡ºäº†å…³é”®ä¸€æ­¥ã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>Inherited retinal diseases (IRDs) are a genetically diverse group of disorders characterized by progressive photoreceptor degeneration, leading to vision loss and blindness. With over 320 associated genes and significant phenotypic variability, effective treatment remains challenging. Recent advances in genome editing, particularly CRISPR/Cas-based technologies, have revolutionized therapeutic approaches by enabling precise and customizable DNA and RNA editing. This review explores the application of various CRISPR strategies-such as gene knockout via non-homologous end joining (NHEJ), exon skipping using dual-sgRNAs, homology-directed repair (HDR), base editing (BE), prime editing (PE), RNA editing with Cas13, and epigenetic modulation through CRISPRa/i-in preclinical models of IRDs. Emphasis is placed on allele-specific targeting, gene-agnostic approaches, and mutation-independent strategies to address dominant and recessive forms of disease. We also highlight recent clinical milestones, including the first human trial using CRISPR gene editing for CEP290-associated Leber congenital amaurosis. Finally, we discuss critical challenges, including delivery constraints, immune responses, and off-target effects, along with emerging solutions such as engineered Cas variants, split-intein systems, and advanced off-target detection methods. Together, these advances underscore the transformative potential of CRISPR technologies in treating IRDs and lay the foundation for future clinical translation.</p>
  </details>
</article>

<article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">Insect science</span>
      <span class="date">2026-02-01</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 25/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/39973047/" target="_blank">Increased versatility and convenience: Advances and strategy optimization of Receptor-Mediated Ovary Transduction of Cargo-mediated genetic modification in insects.</a>
  </h3>
  <p class="title-zh">å¢å¼ºå¤šåŠŸèƒ½æ€§ä¸ä¾¿æ·æ€§ï¼šæ˜†è™«å—ä½“ä»‹å¯¼çš„åµå·¢è´§ç‰©è½¬è¿åŸºå› ä¿®é¥°æŠ€æœ¯çš„è¿›å±•ä¸ç­–ç•¥ä¼˜åŒ–</p>
  <p class="authors">Ling X, Zhou C, Hong JF, Jiang YP, Sun Q, Li LY, Wang SY, Xie XY</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> åŸºå› é€’é€å¹³å°/æŠ€æœ¯ï¼ˆä¸€ç§åŸºäºå—ä½“çš„ä½“å†…é€’é€ç­–ç•¥ï¼ŒéRNAç¼–è¾‘é…¶æœ¬èº«ï¼Œä½†ç”¨äºé€’é€CRISPR-Cas9ç­‰åŸºå› ç¼–è¾‘å·¥å…·è‡³ç‰¹å®šç»„ç»‡ï¼‰</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> è¯¥æŠ€æœ¯çš„æ ¸å¿ƒè®¾è®¡æ€è·¯æ˜¯åˆ©ç”¨æ˜†è™«åµé»„è›‹ç™½åŸå—ä½“ä»‹å¯¼çš„å†…åé€”å¾„ï¼Œå°†èåˆäº†åµé»„è›‹ç™½åŸå—ä½“é…ä½“ï¼ˆå¦‚Yolk proteinï¼‰çš„è´§ç‰©è›‹ç™½ï¼ˆå¦‚Cas9æ ¸ç³–æ ¸è›‹ç™½å¤åˆç‰©ï¼‰ç‰¹å¼‚æ€§é€’é€è‡³åµå·¢ç”Ÿæ®–ç»†èƒã€‚å…¶æ¨¡å—åŒ–ç»„åˆåœ¨äºï¼šé…ä½“æ¨¡å—ï¼ˆè´Ÿè´£é¶å‘è¯†åˆ«ï¼‰ä¸åŠŸèƒ½è´§ç‰©æ¨¡å—ï¼ˆå¦‚åŸºå› ç¼–è¾‘å·¥å…·ï¼‰çš„èåˆï¼Œé€šè¿‡ç®€å•çš„è¡€è…”æ³¨å°„è€Œéèƒšèƒæ˜¾å¾®æ³¨å°„æ¥å®ç°é€’é€ã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. å®ç°æ˜†è™«ç”Ÿæ®–ç³»çš„é«˜æ•ˆåŸºå› ç¼–è¾‘ï¼ˆé€šè¿‡é€’é€CRISPR-Cas9ç­‰å·¥å…·ï¼‰ã€‚
2. ç®€åŒ–åŸºå› ç¼–è¾‘å·¥å…·çš„ä½“å†…é€’é€æµç¨‹ï¼Œé™ä½å¯¹æ˜¾å¾®æ³¨å°„æŠ€æœ¯å’Œè®¾å¤‡çš„è¦æ±‚ã€‚
3. é™ä½åŸºå› æ“ä½œçš„æˆæœ¬å’Œå¤æ‚æ€§ï¼Œæé«˜å®éªŒçš„å¯åŠæ€§ã€‚
4. ä½œä¸ºä¸€ç§é€šç”¨å‹é€’é€å¹³å°ï¼Œç†è®ºä¸Šå¯é€‚é…å¤šç§éœ€è¦é€’é€è‡³åµå·¢çš„è´§ç‰©ï¼ˆå¦‚ä¸åŒçš„æ ¸é…¸é…¶ã€æŠ¥å‘Šè›‹ç™½ç­‰ï¼‰ã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> æœ¬ç»¼è¿°æ€»ç»“äº†è¯¥æŠ€æœ¯åœ¨å¤šç±»æ˜†è™«ç‰©ç§ä¸­å·²è¢«è¯æ˜å…·æœ‰å¯è¡Œæ€§ï¼Œå…¶å…³é”®æ€§èƒ½åœ¨äºèƒ½å¤Ÿç»•è¿‡èƒšèƒæ˜¾å¾®æ³¨å°„ï¼Œé€šè¿‡æ›´ç®€ä¾¿çš„è¡€è…”æ³¨å°„å®ç°é«˜æ•ˆçš„ç”Ÿæ®–ç³»ç¼–è¾‘ï¼Œä½†å…¶å…·ä½“ç¼–è¾‘æ•ˆç‡å’Œè„±é¶æƒ…å†µå–å†³äºæ‰€é€’é€çš„å…·ä½“ç¼–è¾‘å·¥å…·åŠç‰©ç§ï¼Œæ–‡ä¸­æŒ‡å‡ºè¯¥æŠ€æœ¯ä»éœ€åœ¨æ“ä½œç»†èŠ‚å’Œæ•ˆç‡ä¸Šè¿›è¡Œè¿›ä¸€æ­¥ä¼˜åŒ–ã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>Genetic modification via gene editing has become a widely adopted and demonstrably effective method in functional gene research within entomology. However, the optimal efficiency and simplicity of delivering exogenous guide RNA-clustered regularly interspaced short palindromic repeats-associated protein 9 complexes into target tissues are crucial for successful gene editing. The Receptor-Mediated Ovary Transduction of Cargo (ReMOT) strategy, which simplifies the delivery process, target-site selection, technical requirements, and delivery cost compared with embryonic microinjection, enabling efficient editing at the germline level, is gaining increasing attention. Although the feasibility and advantages of this technique have been demonstrated in various insect species, further optimization of operational details and the overcoming of further bottlenecks are still required. This review focuses on advances in developing ReMOT as a valuable technology, exploring its applicability, rationale for selecting the ovary as a delivery target site, factors influencing its efficiency, and improvement recommendations. The versatility and effectiveness of ReMOT make it a promising method for researchers looking to make precise genetic modifications with greater ease and efficiency.</p>
  </details>
</article>

<article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">Biochemical genetics</span>
      <span class="date">2026-02-01</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 25/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/39881080/" target="_blank">Epigenetic Control of Hyperuricemia and Gout by Gene Writer DNMT1 and RNA Editor ADAR1: Mechanism of Gout and Amyloid Dissolution in Down Syndrome.</a>
  </h3>
  <p class="title-zh">é€šè¿‡åŸºå› å†™å…¥å™¨DNMT1å’ŒRNAç¼–è¾‘å™¨ADAR1å¯¹é«˜å°¿é…¸è¡€ç—‡å’Œç—›é£çš„è¡¨è§‚é—ä¼ æ§åˆ¶ï¼šå”æ°ç»¼åˆå¾ä¸­ç—›é£ä¸æ·€ç²‰æ ·è›‹ç™½æº¶è§£çš„æœºåˆ¶</p>
  <p class="authors">Tyagi SC, Smolenkova I, Zheng Y, Singh M</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> ADARä»‹å¯¼çš„RNAç¼–è¾‘ç³»ç»Ÿï¼ˆå†…æºæ€§ADAR1çš„è°ƒæ§ä¸åº”ç”¨ï¼‰</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> æœ¬ç ”ç©¶å¹¶éä»å¤´è®¾è®¡ä¸€ä¸ªå…¨æ–°çš„å·¥ç¨‹åŒ–å·¥å…·ï¼Œè€Œæ˜¯èšç„¦äºåˆ©ç”¨å’Œè°ƒæ§å†…æºæ€§ADAR1çš„RNAç¼–è¾‘æ´»æ€§ã€‚å…¶æ ¸å¿ƒæ€è·¯æ˜¯é€šè¿‡è¯ç†æ‰‹æ®µï¼ˆå¦‚EGCGï¼‰å¹²é¢„ADAR1ä¸Šæ¸¸çš„ä»£è°¢é€šè·¯ï¼ˆå¦‚æŠ‘åˆ¶åŒå‹åŠèƒ±æ°¨é…¸å’Œè…ºè‹·ï¼‰ï¼Œä»è€Œé—´æ¥è°ƒæ§ADAR1çš„æ´»æ€§åŠå…¶ä¸‹æ¸¸äº§ç‰©ï¼ˆå¦‚å°¿é…¸ã€è‚Œé’™è›‹ç™½å°¿é…¸ç›æ²‰ç§¯ï¼‰ï¼Œå¹¶æ¢è®¨å…¶ä¸DNMT1çš„ååŒä½œç”¨ã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. æ­ç¤ºå†…æºæ€§ADAR1æ´»æ€§ä¸ä»£è°¢ç–¾ç—…ï¼ˆé«˜å°¿é…¸è¡€ç—‡ã€ç—›é£ï¼‰çš„å…³è”æœºåˆ¶ã€‚
2. æä¾›é€šè¿‡è°ƒæ§RNAç¼–è¾‘é€šè·¯æ¥å¹²é¢„å”æ°ç»¼åˆå¾ç›¸å…³è¡¨å‹ï¼ˆå¦‚å…ˆå¤©æ€§å¿ƒè„ç—…ã€æ·€ç²‰æ ·è›‹ç™½æ²‰ç§¯ï¼‰çš„æ½œåœ¨ç­–ç•¥ã€‚
3. æå‡ºADAMTS13/TIMP1æ¯”å€¼å¯ä½œä¸ºé¢„æµ‹æ·€ç²‰æ ·æ–‘å—æº¶è§£çš„æ½œåœ¨ç”Ÿç‰©æ ‡å¿—ç‰©ã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> å…³é”®å®éªŒç»“æœè¡¨æ˜ï¼Œä½¿ç”¨è¡¨æ²¡é£Ÿå­å„¿èŒ¶ç´ æ²¡é£Ÿå­é…¸é…¯ï¼ˆEGCGï¼‰ç­‰æŠ‘åˆ¶å‰‚å¤„ç†å”æ°ç»¼åˆå¾æ¨¡å‹å°é¼ ï¼Œèƒ½é™ä½å¿ƒè„ç»„ç»‡ä¸­DNMT1ã€ADARã€TIMP1çš„æ°´å¹³ï¼ŒåŒæ—¶æå‡SAHHã€TET2å’ŒADAMTS12/13çš„æ´»æ€§ï¼Œå¹¶ä¼´éšå¤§è„‘çš®å±‚ä¸­æ·€ç²‰æ ·çº¤ç»´çš„æº¶è§£ï¼Œè¿™æç¤ºé€šè¿‡å¹²é¢„RNAç¼–è¾‘ï¼ˆADARï¼‰åŠç›¸å…³ä»£è°¢é€šè·¯å¯æ”¹å–„å”æ°ç»¼åˆå¾çš„ç—…ç†ç‰¹å¾ã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>Although DNA methyltransferase 1 (DNMT1) and RNA editor ADAR triplications exist in Down syndrome (DS), their specific roles remain unclear. DNMT methylates DNA, yielding S-adenosine homocysteine (SAH), subsequently converted to homocysteine (Hcy) and adenosine by S-adenosine homocysteine (Hcy) hydrolase (SAHH). ADAR converts adenosine to inosine and uric acid. We hypothesized that targeting epigenetic regulators and RNA editor, and inhibiting Hcy and adenosine, could alleviate DS phenotype including the congenital heart disease (CHD). DS and wild-type mice were treated with epigallocatechin gallate (EG), inhibitor of Hcy, and adenosine. Specific substrate gel zymography identified matrix metalloproteinases (MMPs)/A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) activities and MMP12/ADAMTS12 and MMP13/ADAMTS13 levels were assessed via gel zymography. Cardiac levels of DNMT1, ADAR, tissue inhibitor of metalloproteinase 1 (TIMP1), SAHH, and ten-eleven translocator (TET2), along with hydroxymethylation (a gene eraser), were measured. Calcium urate deposits in heart tissue suggested gout mechanism in DS. Robust amyloid fibers in DS mouse brain cortex were most likely dissolved by ADAMTS as its levels were elevated in tissues, with a corresponding decrease in TIMP1 in the EG group. It appears that triplication of down syndrome cell adhesion molecule (DSCAM) and cell adhesion molecule 1 (CAM1) fragment also help dissolve amyloid fibers, thus suggesting ADAMTS13/TIMP1 ratio could predict plaque dissolution. Our results indicate that cystathionine-Î² synthase (CBS) inhibitor as a potential therapy for amyloid dissolution.</p>
  </details>
</article>
  </main>

  <footer>
    <p>æ•°æ®æ¥æº: <a href="https://pubmed.ncbi.nlm.nih.gov/" target="_blank">PubMed</a></p>
    <p>AI æ’åº/æ€»ç»“: DeepSeek</p>
  </footer>
</body>
</html>
